New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
04:55 EDTBLUE, BLUE, BLUE, BLUE, ACE, ACE, ACE, ACE, XLRN, XLRN, XLRN, XLRN, TGTX, TGTX, TGTX, TGTX, NVS, NVS, NVS, NVS, AGIO, AGIO, AGIO, AGIO, AG, AG, AG, AGEuropean Hematology Association to hold a conference
19th Congress of the European Hematology Association will be held in Milan, Italy on June 12-15.
News For BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 21, 2014
15:30 EDTACENotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Yahoo! (YHOO), consensus 30c; ACE (ACE), consensus $2.34; Discover Financial (DFS), consensus $1.34; Pinnacle Financial (PNFP), consensus 51c; Broadcom (BRCM), consensus 84c; Intuitive Surgical (ISRG), consensus $3.80; FMC Technologies (FTI), consensus 74c; Robert Half International (RHI), consensus 58c; E-Trade (ETFC), consensus 22c; Nabors Industries (NBR), consensus 36c; Waste Connections (WCN), consensus 54c; Cubist Pharmaceuticals (CBST), consensus 4c; Sonic (SONC), consensus 34c; American Campus Communities (ACC), consensus 43c; Cree (CREE), consensus 36c; Fulton Financial (FULT), consensus 20c; Costamare (CMRE), consensus 41c; Hawaiian Holdings (HA), consensus 78c; Ethan Allen (ETH), consensus 36c; Sabra Health (SBRA), consensus 55c; Rush Enterprises (RUSHA), consensus 51c.
08:46 EDTACEACE receives regulatory aprovals to close acquisition of P&C business
Subscribe for More Information
08:40 EDTAGIOAgios Pharmaceuticals initiates Phase 1/2 clinical trial of AG-221
Subscribe for More Information
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTBLUE, AGIOFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
October 17, 2014
16:22 EDTTGTXRA Capital reports 8.3% passive stake in TG Therapeutics
14:50 EDTNVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
October 15, 2014
17:03 EDTNVSNovartis announces CTL019 data demonstrating efficacy in certain ALL patients
Novartis and the University of Pennsylvania's Perelman School of Medicine announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine, or NEJM, evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia, or r/r ALL. The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor, or CAR, therapy CTL019. Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA. Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78%.
10:57 EDTXLRNAcceleron to host educational webcast
Educational webcast on Beta-thalassemia will be held on October 17 at 12:30 pm. Webcast Link
10:52 EDTXLRNAcceleron management to meet with FBR Capital
Subscribe for More Information
07:40 EDTAGIOAgios Pharmaceuticals initiates four expansion cohorts in AG-221 Phase 1 study
Subscribe for More Information
06:05 EDTACEACE Limited creates new distribution unit in Asia Pacific
Subscribe for More Information
06:00 EDTACEACE Limited creates new distribution, client management unit in Asia Pacific
ACE Group announced the creation of a new unit to focus solely on the execution of distribution strategies across the Asia Pacific region. Enabling a high-level and efficient conduit between ACE and its distribution partners throughout the vast territory stretching from South Korea to Australia and New Zealand, this unit will focus on maximizing ACE’s product offering including portfolio-based solutions, facilities, joint product design and execution initiatives with key brokers in the region. Additionally, the unit will serve the unique needs of ACE’s large clients domiciled in Asia Pacific with the ultimate mission to ensure efficient trading across all commercial lines of business; providing distribution partners and clients with relevant and timely products backed by the strength of ACE’s balance sheet.
October 14, 2014
11:23 EDTNVSBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
07:33 EDTXLRNAcceleron initiates ACE-083 Phase 1 clinical trial
Subscribe for More Information
07:08 EDTAGFirst Majestic reports Q3 silver production in Mexico up 5% YoY
First Majestic Silver announced that total production at its five operating silver mines in Mexico for the Q3 ending September 30 reached 3,523,536 equivalent ounces of silver, representing a 5% increase compared to the same quarter in 2013. Total silver production for the quarter consisted of 2,680,439 ounces of silver, relatively unchanged compared to the same quarter in 2013. In addition, 9,703,792 pounds of lead and 3,222,877 pounds of zinc were produced, representing an increase of 14% and 44%, respectively, compared to the same quarter of the previous year. Also produced were 2,781 ounces of gold, representing a 5% decrease compared to the Q3 of 2013.
07:04 EDTBLUEbluebird bio says first patient with sicle cell disease undergoes infusion
Subscribe for More Information
October 10, 2014
05:13 EDTNVSNovartis reports new analyses of AIN457 Phase III data show consistent efficacy
Novartis announced that new analyses of AIN457 Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity. Secukinumab's new mode of action stops interleukin-17A, which plays a central role in the development of psoriasis. In the analyses, the majority of patients across two disease severity subgroups, including those with severe psoriasis, experienced complete clear to almost clear skin measured as 100 or 90% reduction of respective baseline PASI, or Psoriasis Area and Severity Index. Skin clearance was sustained through one year of treatment. This is important as historically, psoriasis patients' disease severity at the start of treatment has been shown to negatively impact their response to other therapies. Disease severity subgroups were PASI less than or equal to 20 and PASI greater than 20. PASI measures redness, scaling and thickness of psoriatic plaques and the impact in regions of the body. These findings reconfirm the significantly better responses seen in the published FIXTURE study, where secukinumab showed superiority to Enbrel, a standard of care anti-TNF medication.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use